|By Marketwired .||
|May 12, 2014 06:00 AM EDT||
FOSTER CITY, CA -- (Marketwired) -- 05/12/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the first quarter ended March 31, 2014.
- Revenues: Revenues for the first quarter 2014 were $26.6 million, compared to $29.8 million for the same period in 2013. On the basis of the Company's core business, which includes ZADAXIN®, Aggrastat® and all Pfizer and Baxter products, revenues in the first quarter represent a growth of 31%.
- GAAP Basic EPS: GAAP basic earnings per share for the first quarter 2014 were $0.08, compared to $0.08 for the same period in 2013.
- Non-GAAP Basic EPS: Non-GAAP basic earnings per share for the first quarter 2014 were $0.10, compared to $0.10 for the same period in 2013.
ZADAXIN revenues were $24.7 million for the first quarter 2014, a $5.7 million or 30% increase, compared to $19.0 million in the same period in 2013. SciClone believes its ZADAXIN product revenues in the first half of 2013, and the fourth quarter of 2012, were adversely affected by the increase in channel inventory it experienced in the latter half of 2012, and believes that ZADAXIN channel inventory has now returned to normal levels. Promotion services revenues were $0.5 million for the first quarter of 2014, derived mainly from the Company's product promotion agreement with Baxter. As a result of the expiration of the promotion agreements with Sanofi Aventis S.A. ("Sanofi") at the end of their term on December 31, 2013, the Company's promotion agreement revenues were $8.8 million or 95% lower compared to $9.3 million recorded in the same period in 2013.
On a GAAP basis, SciClone reported net income for the first quarter of 2014 of $4.1 million or $0.08 per share on both a basic and diluted basis for the first quarter 2014, compared to net income of $4.2 million for the same period in the prior year or $0.08 per share on both a basic and diluted basis for the same period in the prior year.
SciClone's non-GAAP net income for the first quarter of 2014 was $5.0 million or $0.10 and $0.09 per share on a basic and diluted basis, respectively, compared to $5.2 million or $0.10 and $0.09 per share on a basic and diluted basis, respectively, for the same period of last year.
"We are pleased with our performance in the first quarter of 2014, especially relative to the continuation of strong growth in ZADAXIN sales which began to resume in the fourth quarter of 2013," said Friedhelm Blobel, Ph.D., SciClone's Chief Executive Officer. "We believe that the sales and marketing strategies we have implemented over the last several months are succeeding in driving demand and increasing market penetration. We have seen a meaningful increase in the number of hospital departments where ZADAXIN is being prescribed, and an increase in the number of customers within established departments already utilizing ZADAXIN, thus underscoring the successful implementation of our 'wider and deeper' strategy. We believe that we are on track to achieve our guidance for the year, and are optimistic that we will continue to see growth in ZADAXIN sales, as well as in our primary care/cardiovascular and oncology businesses this year. We see evidence that the China pharmaceuticals market is growing again at a robust rate, and continues to represent a significant opportunity for SciClone. We are actively engaged in seeking additional business development opportunities to further expand our product portfolio, and believe that we are well-positioned to attract new partners. We are committed to continuing our strong focus on constant improvement in our company-wide compliance program, and believe that is a key, differentiating asset for our Company."
Sales and marketing expenses for the first quarter of 2014 were $9.8 million, compared with $11.2 million for the same period of the prior year. SciClone restructured its sales force in the fourth quarter of 2013 related to the expiration of the Sanofi distribution agreements, and the sales force has been reduced by over 200 salespersons by March 31, 2014, compared to one year ago. In addition, sales and marketing expenses decreased for the first quarter of 2014 related to the expiration of the Sanofi agreements and the reduction in costs associated with marketing the products under these agreements. These reductions were partially offset by growth in the sales and marketing efforts for ZADAXIN.
Research and development (R&D) expenses for the first quarter of 2014 were $1.5 million, compared with $0.4 million of R&D expenses for the same period of last year, an increase of $1.1 million, primarily related to costs incurred in the evaluation of potential sepsis clinical studies for ZADAXIN.
General and administrative (G&A) expenses for the first quarter of 2014 were $6.0 million, compared with $8.6 million for the same period in the prior year, primarily related to lower legal costs associated with the ongoing government investigation and other legal matters and lower accounting fees that were incurred in the prior year period related to the restatement of the consolidated financial statements for the year ended December 31, 2011, and certain quarters of 2011 and 2012.
As of March 31, 2014, cash and cash equivalents, restricted cash and investments totaled $87.5 million, compared to $85.9 million as of December 31, 2013. SciClone has a share repurchase program under which its Board of Directors authorized $50.5 million, of which approximately $43.4 million had been utilized through March 31, 2014, and approximately $7.1 million remained available.
SciClone has presented non-GAAP information above as the Company believes this non-GAAP information is useful for investors, taken in conjunction with SciClone's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of SciClone's operating results as reported under GAAP. The non-GAAP calculations and reconciliation are provided in the accompanying table titled "Reconciliation of GAAP to Non-GAAP Net Income."
Conference Call Today
SciClone is hosting a conference call today at 8:30 am ET (5:30 am PT) to provide a financial update. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
(Replay available from May 12, 2014, at 12:30 pm ET until 11:59 pm ET on May 19, 2014)
The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties relating to: the course, cost and outcome of regulatory matters, including future pricing decisions by authorities in China; the on-going regulatory investigations and expenses related thereto, including potential fines and/or other remedies; the Company's ability to execute on its goals in China and on its objectives for revenue in fiscal 2014; the dependence of its current and future revenue and prospects on third-party license, promotion or distribution agreements, including the need to renew such agreements, enter into similar agreements, or end arrangements that the Company does not believe are beneficial; the uncertainties as to the impact of the non-renewal of our agreement with Sanofi; operating an international business; uncertainty in the prospects for unapproved products, including ProFlow and Neucardin®, including uncertainties as to pricing and competition and risks relating to the clinical trial process and related regulatory approval process and the process of initiating trials at, and enrolling patients at, clinical sites; and the effect of changes in its practices and policies related to the Company's compliance programs. SciClone cannot predict the timing or outcome of the ongoing SEC and DOJ investigations, or of the level of its efforts required to cooperate with those investigations, however, the Company has incurred substantial expenses in connection with the investigations and related litigation and expects to incur substantial additional expense, and the investigations could result in fines that exceed the minimum amount accrued and further changes in its internal control or other remediation measures that could adversely affect its financial results. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
SCICLONE PHARMACEUTICALS, INC. UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share amounts) Three Months Ended March 31, ------------------------ 2014 2013 ----------- ----------- Revenues: Product sales, net $ 26,064 $ 20,533 Promotion services 501 9,273 ----------- ----------- Total net revenues 26,565 29,806 Operating expenses: Cost of product sales 4,561 4,618 Sales and marketing 9,834 11,199 Research and development 1,476 365 General and administrative 6,033 8,600 ----------- ----------- Total operating expenses 21,904 24,782 ----------- ----------- Income from operations 4,661 5,024 Non-operating income (expense): Interest income 19 19 Interest expense (29) (37) Other expense, net (119) (16) ----------- ----------- Income before provision for income tax 4,532 4,990 Provision for income tax 398 787 ----------- ----------- Net income $ 4,134 $ 4,203 =========== =========== Basic net income per share $ 0.08 $ 0.08 Diluted net income per share $ 0.08 $ 0.08 Weighted average shares used in computing: Basic net income per share 52,026 54,084 Diluted net income per share 53,234 55,472 SCICLONE PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP NET INCOME (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, ----------------------- 2014 2013 ----------- ----------- GAAP net income $ 4,134 $ 4,203 Non-GAAP adjustment: Employee stock-based compensation 882 1,019 ----------- ----------- Non-GAAP net income $ 5,016 $ 5,222 =========== =========== Non-GAAP basic net income per share $ 0.10 $ 0.10 Non-GAAP diluted net income per share $ 0.09 $ 0.09 Weighted average shares used in computing: Non-GAAP basic net income per share 52,026 54,084 Non-GAAP diluted net income per share 53,234 55,472
SciClone management uses these non-GAAP financial measures to monitor and evaluate the Company's operating results and trends on an on-going basis and internally for operations, budgeting and financial planning purposes. SciClone believes the non-GAAP information is useful for investors by offering them the ability to better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expenses that affect SciClone. These non-GAAP financial measures that management uses are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP.
SciClone's non-GAAP financial measures exclude the following item from GAAP net income and net income per share:
- Employee stock-based compensation. The effects of non-cash employee stock-based compensation.
SCICLONE PHARMACEUTICALS, INC. UNAUDITED SELECTED BALANCE SHEET DATA (in thousands) March 31, December 31, 2014 2013 ------------- ------------- Cash, cash equivalents, and restricted cash and investments $ 87,545 $ 85,878 Accounts receivable 32,271 40,008 Inventories 14,049 15,238 Goodwill 34,435 35,357 Total assets 172,192 180,227 Total current liabilities 23,560 33,588 Deferred tax liabilities 101 368 Short-term borrowings 1,608 1,651 Total shareholders' equity 148,455 146,595
SYS-CON Events announced today that Soha will exhibit at SYS-CON's DevOps Summit New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Soha delivers enterprise-grade application security, on any device, as agile as the cloud. This turnkey, cloud-based service enables customers to solve secure application access and delivery challenges that traditional or virtualized network solutions cannot solve because they are too expensive, inflexible and operational...
Apr. 25, 2015 03:45 PM EDT Reads: 1,664
Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 16th Cloud Expo at the Javits Center in New York June 9-11 will find fresh new content in a new track called PaaS | Containers & Microservices Containers are not being considered for the first time by the cloud community, but a current era of re-consideration has pushed them to the top of the cloud agenda. With the launch ...
Apr. 25, 2015 03:00 PM EDT Reads: 2,845
Health care systems across the globe are under enormous strain, as facilities reach capacity and costs continue to rise. M2M and the Internet of Things have the potential to transform the industry through connected health solutions that can make care more efficient while reducing costs. In fact, Vodafone's annual M2M Barometer Report forecasts M2M applications rising to 57 percent in health care and life sciences by 2016. Lively is one of Vodafone's health care partners, whose solutions enable o...
Apr. 25, 2015 03:00 PM EDT Reads: 1,499
SYS-CON Events announced today that Ciqada will exhibit at SYS-CON's @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Ciqada™ makes it easy to connect your products to the Internet. By integrating key components - hardware, servers, dashboards, and mobile apps - into an easy-to-use, configurable system, your products can quickly and securely join the internet of things. With remote monitoring, control, and alert messaging capability, you will mee...
Apr. 25, 2015 03:00 PM EDT Reads: 1,906
of cloud, colocation, managed services and disaster recovery solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. TierPoint, LLC, is a leading national provider of information technology and data center services, including cloud, colocation, disaster recovery and managed IT services, with corporate headquarters in St. Louis, MO. TierPoint was formed through the strategic combination of some of t...
Apr. 25, 2015 02:30 PM EDT Reads: 1,648
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
Apr. 25, 2015 02:00 PM EDT Reads: 2,491
While not quite mainstream yet, WebRTC is starting to gain ground with Carriers, Enterprises and Independent Software Vendors (ISV’s) alike. WebRTC makes it easy for developers to add audio and video communications into their applications by using Web browsers as their platform. But like any market, every customer engagement has unique requirements, as well as constraints. And of course, one size does not fit all. In her session at WebRTC Summit, Dr. Natasha Tamaskar, Vice President, Head of C...
Apr. 25, 2015 02:00 PM EDT Reads: 1,770
Public Cloud IaaS started it's life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small and medium sized business have server closets and colocation footprints filled with servers and storage gear. While on-premise environment virtualization may have peaked at 75%, the Public Cloud has lagged in ado...
Apr. 25, 2015 02:00 PM EDT Reads: 1,258
Dave will share his insights on how Internet of Things for Enterprises are transforming and making more productive and efficient operations and maintenance (O&M) procedures in the cleantech industry and beyond. Speaker Bio: Dave Landa is chief operating officer of Cybozu Corp (kintone US). Based in the San Francisco Bay Area, Dave has been on the forefront of the Cloud revolution driving strategic business development on the executive teams of multiple leading Software as a Services (SaaS) ap...
Apr. 25, 2015 02:00 PM EDT Reads: 1,544
SYS-CON Events announced today that GENBAND, a leading developer of real time communications software solutions, has been named “Silver Sponsor” of SYS-CON's WebRTC Summit, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. The GENBAND team will be on hand to demonstrate their newest product, Kandy. Kandy is a communications Platform-as-a-Service (PaaS) that enables companies to seamlessly integrate more human communications into their Web and mobile applicatio...
Apr. 25, 2015 01:00 PM EDT Reads: 2,716
ProfitBricks, the provider of painless cloud infrastructure IaaS, today released its SDK for Ruby, written against the company's new RESTful API. The new SDK joins ProfitBricks' previously announced support for the popular multi-cloud open-source Fog project. This new Ruby SDK, which exposes advanced functionality to take advantage of ProfitBricks' simplicity and productivity, aligns with ProfitBricks' mission to provide a painless way to automate infrastructure in the cloud. Ruby is a genera...
Apr. 25, 2015 01:00 PM EDT Reads: 1,043
SYS-CON Events announced today that BroadSoft, the leading global provider of Unified Communications and Collaboration (UCC) services to operators worldwide, has been named “Gold Sponsor” of SYS-CON's WebRTC Summit, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. BroadSoft is the leading provider of software and services that enable mobile, fixed-line and cable service providers to offer Unified Communications over their Internet Protocol networks. The Compa...
Apr. 25, 2015 12:30 PM EDT Reads: 2,524
Apr. 25, 2015 12:15 PM EDT Reads: 1,318
ProfitBricks has launched its new DevOps Central and REST API, along with support for three multi-cloud libraries and a Python SDK. This, combined with its already existing SOAP API and its new RESTful API, moves ProfitBricks into a position to better serve the DevOps community and provide the ability to automate cloud infrastructure in a multi-cloud world. Following this momentum, ProfitBricks has also introduced several libraries that enable developers to use their favorite language to code ...
Apr. 25, 2015 12:00 PM EDT Reads: 1,685
What exactly is a cognitive application? In her session at 16th Cloud Expo, Ashley Hathaway, Product Manager at IBM Watson, will look at the services being offered by the IBM Watson Developer Cloud and what that means for developers and Big Data. She'll explore how IBM Watson and its partnerships will continue to grow and help define what it means to be a cognitive service, as well as take a look at the offerings on Bluemix. She will also check out how Watson and the Alchemy API team up to off...
Apr. 25, 2015 12:00 PM EDT Reads: 1,833